Holen Sie sich die Stockscreener-App
1.71
4.47%
-0.08
Handel nachbörslich:
1.64
-0.07
-4.09%
Schlusskurs vom Vortag:
$1.79
Offen:
$1.72
24-Stunden-Volumen:
712.11K
Relative Volume:
10.62
Marktkapitalisierung:
$57.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.26M
KGV:
-0.0904
EPS:
-18.9056
Netto-Cashflow:
$-15.62M
1W Leistung:
-11.86%
1M Leistung:
-44.12%
6M Leistung:
-71.74%
1J Leistung:
-58.89%
1-Tages-Spanne:
$1.6246
$1.81
1-Wochen-Bereich:
$1.6246
$2.17
52-Wochen-Spanne:
$1.6246
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Firmenname
Dogwood Therapeutics Inc
Sektor
Branche
Telefon
(866) 620-8655
Adresse
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.71 | 59.79M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Decliners Report: How volatile is Dogwood Therapeutics Inc stock2026 Market WrapUp & AI Driven Stock Movement Reports - baoquankhu1.vn
Will Dogwood Therapeutics Inc benefit from government policyCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Investment Report: Will Dogwood Therapeutics Inc benefit from geopolitical trends2026 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-04-11 05:48:42 - baoquankhu1.vn
Activity Recap: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Performance Recap: How sensitive is Dogwood Therapeutics Inc to inflationEarnings Summary Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Weekly: Should I invest in Dogwood Therapeutics Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Downgrade Watch: How sensitive is Dogwood Therapeutics Inc to inflationMarket Sentiment Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Sentiment Watch: What is the PEG ratio of Dogwood Therapeutics IncCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Dogwood Therapeutics Reports Q1 2026 Progress: Advances in Halneuron® and SP16 for Cancer-Related Pain and Neuropathy, $12.5M Raised - Minichart
Analysts Issue Forecasts for DWTX Q1 Earnings - Defense World
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway - TipRanks
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Q1 Earnings Estimate for DWTX Issued By Zacks Research - MarketBeat
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - MarketBeat
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
Dogwood Therapeutics (DWTX) SVP awarded 82,500-share stock option grant - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):